mAbxience |

INSUD PHARMA is the new name of Chemo Group

11/24/2017

Therefore, our three pharma brands, Chemo, Exeltis and mAbxience, are now grouped together under this name. This new identity is the result of the development and diversification of the company’s pharma activity. Madrid, 24 November 2017–From now on, Chemo Group, the pharmaceutical multinational that is present in over 40 countries, is going to be called […]

Meet us at CPhI Worldwide!

09/17/2017

Meet us at CPhI Worldwide! Between 24th and 26th October the CPhI Worldwide Congress 2017 will take place in Frankfurt (Germany).   Details When? Between 24th and 26th October Where? Frankfurt (Germany)

mAbxience analyses getting a new plant in Argentina

07/31/2017

The company is part of the multinational CHEMO group, with 40 years’ experience in the pharmaceutical industry and presence in more than 40 countries. The biotechnology company dedicated to the R&D, manufacture and commercialisation of drugs, mainly biosimilars medicines, already has an R&D centre in Spain, together with a monoclonal antibody production plant in Munro, […]

BAC León 2017

07/13/2017

Between 12th and 14th July the Biotech Annual Congress (BAC) 2017 will take place in León (Spain), organised by FEBiotech, the Spanish Federation of Biotechnologists. This event offers a great meeting point of a high scientific level, bringing together Biotech students with researchers and professionals from different areas of this discipline.   Within the mentoring […]

mAbxience at EACPT 2017

06/27/2017

Within the framework of the 13th Congress of the European Association of Clinical and Therapeutic Pharmacology (EACPT), held in Prague between 24th and 27th June, Dr Francisco Javier Fernández, medical advisor at mAbxience, presented the results of the population pharmacokinetic modelling the Rituximab (RTXM83) clinical study. It is an international clinical study conducted in 58 […]

13th Congress of the European Association of Clinical Pharmacology and Therapeutics (EACPT)

06/27/2017

On June 27th Dr Francisco Javier Fernández, mAbxience Medical Advisor, will present the results of the population pharmacokinetic modelling of mAbxience’s rituximab clinical study at the 13th Congress of the European Association of Clinical Pharmacology and Therapeutics (EACPT), to be held in Prague from 24th to 27th June.   When: 27th June Where: Clarion Congress Hotel Prague – Freyova 33 […]